These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29996373)

  • 1. [Research advances in the v-raf murine sarcoma viral oncogene homolog gene mutation in ameloblastoma].
    Yan XC; Sun LS; Dong ZW; You Z; Dong Q
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Jul; 53(7):500-502. PubMed ID: 29996373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
    Brown NA; Rolland D; McHugh JB; Weigelin HC; Zhao L; Lim MS; Elenitoba-Johnson KS; Betz BL
    Clin Cancer Res; 2014 Nov; 20(21):5517-26. PubMed ID: 24993163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Mutational Profile of Unicystic Ameloblastoma.
    Heikinheimo K; Huhtala JM; Thiel A; Kurppa KJ; Heikinheimo H; Kovac M; Kragelund C; Warfvinge G; Dawson H; Elenius K; Ristimäki A; Baumhoer D; Morgan PR
    J Dent Res; 2019 Jan; 98(1):54-60. PubMed ID: 30216733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: A review.
    You Z; Liu SP; Du J; Wu YH; Zhang SZ
    J Oral Pathol Med; 2019 Mar; 48(3):201-205. PubMed ID: 30489659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An immunohistochemical and genetic study of BRAF
    Seki-Soda M; Sano T; Ito K; Yokoo S; Oyama T
    Pathol Int; 2020 Apr; 70(4):224-230. PubMed ID: 31930640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation.
    Fernandes GS; Girardi DM; Bernardes JPG; Fonseca FP; Fregnani ER
    BMC Cancer; 2018 Sep; 18(1):887. PubMed ID: 30208863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High frequency of BRAF V600E mutations in ameloblastoma.
    Kurppa KJ; Catón J; Morgan PR; Ristimäki A; Ruhin B; Kellokoski J; Elenius K; Heikinheimo K
    J Pathol; 2014 Apr; 232(5):492-8. PubMed ID: 24374844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress towards personalized medicine for ameloblastoma.
    Gomes CC; Diniz MG; Gomez RS
    J Pathol; 2014 Apr; 232(5):488-91. PubMed ID: 24749150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ameloblastoma with mucous cells: A clinicopathological, BRAF mutation, and MAML2 rearrangement study.
    Xia RH; Zhang CY; Sun JJ; Tian Z; Hu YH; Gu T; Wang LZ; Li J
    Oral Dis; 2020 May; 26(4):805-814. PubMed ID: 31954088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF V600E mutation mediates invasive and growth features in ameloblastoma.
    Zhang CX; Zhang LZ; Lin H; Man QW; Liu B
    Oral Dis; 2024 Oct; 30(7):4426-4439. PubMed ID: 38424736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAFV600E: implications for carcinogenesis and molecular therapy.
    Cantwell-Dorris ER; O'Leary JJ; Sheils OM
    Mol Cancer Ther; 2011 Mar; 10(3):385-94. PubMed ID: 21388974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF V600E mutation detected in cell-free DNA from conventional ameloblastomas fluid aspirate.
    Martins-de-Barros AV; Barros AMI; Lazo RJGS; Barbosa Neto AG; Araújo FADC; Carvalho MV
    Oral Dis; 2024 Sep; 30(6):3962-3965. PubMed ID: 38168084
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of recurrent SMO and BRAF mutations in ameloblastomas.
    Sweeney RT; McClary AC; Myers BR; Biscocho J; Neahring L; Kwei KA; Qu K; Gong X; Ng T; Jones CD; Varma S; Odegaard JI; Sugiyama T; Koyota S; Rubin BP; Troxell ML; Pelham RJ; Zehnder JL; Beachy PA; Pollack JR; West RB
    Nat Genet; 2014 Jul; 46(7):722-5. PubMed ID: 24859340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of MDM2 Overexpression in Ameloblastomas with
    Tosios KI; Kalogirou EM; Koutlas IG
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF V600E and previously unidentified KRAS G12C mutations in odontogenic tumors may affect MAPK activation differently depending on tumor type.
    Oh KY; Kim JH; Cho SD; Yoon HJ; Lee JI; Hong SD
    Genes Chromosomes Cancer; 2022 Aug; 61(8):481-490. PubMed ID: 35353428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. K-Ras gene status and expression of Ras/mitogen-activated protein kinase (MAPK) signaling molecules in ameloblastomas.
    Kumamoto H; Takahashi N; Ooya K
    J Oral Pathol Med; 2004 Jul; 33(6):360-7. PubMed ID: 15200485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic study of the BRAF gene reveals new variants and high frequency of the V600E mutation among Iranian ameloblastoma patients.
    Soltani M; Tabatabaiefar MA; Mohsenifar Z; Pourreza MR; Moridnia A; Shariati L; Razavi SM
    J Oral Pathol Med; 2018 Jan; 47(1):86-90. PubMed ID: 28650588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi.
    Uribe P; Andrade L; Gonzalez S
    J Invest Dermatol; 2006 Jan; 126(1):161-6. PubMed ID: 16417232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ameloblastic fibrosarcoma: clinicopathological and molecular analysis of seven cases highlighting frequent BRAF and occasional NRAS mutations.
    Agaimy A; Skalova A; Franchi A; Alshagroud R; Gill AJ; Stoehr R; Baumhoer D; Bauer S
    Histopathology; 2020 May; 76(6):814-821. PubMed ID: 31899815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and evaluation of the presence of the BRAF V600E mutation in ameloblastomas in an Indian population.
    Goes CF; Spadigam A; Dhupar A; Carvalho KM; Cota J; Syed S
    Indian J Pathol Microbiol; 2023; 66(2):246-251. PubMed ID: 37077063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.